120 related articles for article (PubMed ID: 16265258)
1. Current state of the art for cardiac arrhythmia gene therapy.
Donahue JK
Pharmacol Ther; 2017 Aug; 176():60-65. PubMed ID: 28642118
[TBL] [Abstract][Full Text] [Related]
2. Cardiomyocyte electrophysiology and its modulation: current views and future prospects.
Huang CL; Lei M
Philos Trans R Soc Lond B Biol Sci; 2023 Jun; 378(1879):20220160. PubMed ID: 37122224
[TBL] [Abstract][Full Text] [Related]
3. Cardiac arrhythmogenesis: a tale of two clocks?
Lei M; Huang CL
Cardiovasc Res; 2020 Dec; 116(14):e205-e209. PubMed ID: 31800017
[No Abstract] [Full Text] [Related]
4. Atrial Fibrillation: The Science behind Its Defiance.
Czick ME; Shapter CL; Silverman DI
Aging Dis; 2016 Oct; 7(5):635-656. PubMed ID: 27699086
[TBL] [Abstract][Full Text] [Related]
5. Do we need pharmacological therapy for atrial fibrillation in the ablation era?
Lévy S
J Interv Card Electrophysiol; 2006 Dec; 17(3):189-94. PubMed ID: 17340189
[TBL] [Abstract][Full Text] [Related]
6. Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes.
Fredj S; Lindegger N; Sampson KJ; Carmeliet P; Kass RS
Circ Res; 2006 Nov; 99(11):1225-32. PubMed ID: 17082480
[TBL] [Abstract][Full Text] [Related]
7. Neural modulation of cardiac arrhythmias and sudden cardiac death.
Zipes DP; Rubart M
Heart Rhythm; 2006 Jan; 3(1):108-13. PubMed ID: 16399065
[No Abstract] [Full Text] [Related]
8. Mechanisms of disease: new mechanisms of antiarrhythmic actions.
Gilmour RF; Zipes DP
Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):37-41. PubMed ID: 16265258
[TBL] [Abstract][Full Text] [Related]
9. Future of antiarrhythmic drugs.
Darbar D; Roden DM
Curr Opin Cardiol; 2006 Jul; 21(4):361-7. PubMed ID: 16755206
[TBL] [Abstract][Full Text] [Related]
10. Model systems for the discovery and development of antiarrhythmic drugs.
Nattel S; Duker G; Carlsson L
Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282
[TBL] [Abstract][Full Text] [Related]
11. A focus on antiarrhythmic properties of ranolazine.
Vizzardi E; D'Aloia A; Quinzani F; Bonadei I; Rovetta R; Bontempi L; Curnis A; Dei Cas L
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919
[TBL] [Abstract][Full Text] [Related]
12. Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias.
Dai DZ; Yu F
Acta Pharmacol Sin; 2005 Aug; 26(8):918-25. PubMed ID: 16038623
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic drug target choices and screening.
Sanguinetti MC; Bennett PB
Circ Res; 2003 Sep; 93(6):491-9. PubMed ID: 14500332
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
